TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02644252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Cisplatin 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Cisplatin 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Vinorelbine 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Vinorelbine 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 8: Capsule vinorelbine 50 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 8: Capsule vinorelbine 50 mg/m2
Study: NCT04333108

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
Study: NCT03337165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tolerogenic dendritic cells
Description: dose-escalation
Study: NCT03852173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wasserschulen
Description: Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents
Study: NCT01831765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
Study: NCT03322618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 7 tubes of 6 ml (42 ml of blood )

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 7 tubes of 6 ml (42 ml of blood )

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: 7 tubes of 6 ml (42 ml of blood )
Study: NCT02149290

Intervention type: DEVICE
Intervention: Trends-equipped LifeVest 4000
Description: LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
Study: NCT02314091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: onlay mesh hernioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: onlay mesh hernioplasty
Study: NCT00899990

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02299271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.375% ropivacaine as a one-time, 60 milliliter injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as a one-time, 60 milliliter injection.
Study: NCT00768157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical resection of HBV-related HCC
Description: Procedure/Surgery - radical resection of HBV-related HCC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical resection of HBV-related HCC
Description: Procedure/Surgery - radical resection of HBV-related HCC
Study: NCT03426813

Intervention type: OTHER
Group type: OTHER
Intervention: Historical control group for early mobilization
Study: NCT01335191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (1.0 mg)
Description: Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
Study: NCT01482468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of palonosetron added to prophylactic single injection of palonosetron
Description: continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: continuous infusion of normal saline added to prophylactic single injection of palonosetron
Description: continuous infusion of normal saline after single injection of palonosetron 0.075mg
Study: NCT01478061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anastomosis (C-Port® )
Description: creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
Study: NCT03563261

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen supplement group
Description: Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement group
Description: Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
Study: NCT01728727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC-MSC transplantation
Description: After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Participants will receive conventional treatment and antiviral treatment.
Study: NCT03261570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: 60mg by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 0.5 (500mcg) by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lactulose 50mg by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lactulose 50mg by mouth
Study: NCT01261260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Uridine
Description: 1 gram tablets BID for 7 days
Study: NCT01052831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50-100 mg qd for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50-100 mg qd for 8 weeks
Study: NCT01191281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet/nutrition counsel+food aid
Description: Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary/nutrition counsel
Description: Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
Study: NCT03790540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe
Description: It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Benzocaine 20%
Description: Topical benzocaine 20% gel on the mucosal injection site prior to injection
Study: NCT05070325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application group
Description: Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shotblocker group
Description: Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
Study: NCT00838383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan (Thelin)
Description: sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan (Thelin)
Description: Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
Study: NCT04266158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myoelectric UE Device-UE Orthosis-No Device
Description: all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myoelectric UE Device-UE Orthosis-No Device
Description: all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myoelectric UE Device-UE Orthosis-No Device
Description: all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
Study: NCT03678818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Latrunculin A
Description: A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
Study: NCT01564602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comparison multiple channel port laparoscopic surgery
Description: to compare 2-channel single port and multiple channel port laparoscopic surgery
Study: NCT02254551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
Study: NCT03648463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection
Description: Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection
Description: Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
Study: NCT01784003

Intervention type: DEVICE
Intervention: Powered ankle-foot prosthesis
Study: NCT02644252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Carboplatin AUC=5
Study: NCT05022043

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Presepsin
Description: Estimation of Serum Presepsin at time of admission
Study: NCT00565019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: * Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: \>10 cm2, dosage 100-120 mg
Study: NCT01999712

Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
Study: NCT02720250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 chicken eggs
Description: Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular chicken eggs
Description: Intake of 3 regular chicken eggs per day for three weeks.
Study: NCT02019017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 25 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 50 IU
Study: NCT00639496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine
Description: 600 mg x 3, for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT00539318

Intervention type: PROCEDURE
Intervention: Blood drawing
Description: Once when enroll in study
Study: NCT04366713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Administered orally once daily as a single daily dose of 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Administered orally for prophylaxis for 28 days and then as needed
Study: NCT00788918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Description: Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
Study: NCT00846469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CCTA (coronary computed tomography angiography)
Description: A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control section
Description: Normal emergency room treatment for symptoms of chest pain.
Study: NCT02639923

Intervention type: PROCEDURE
Intervention: Drawing of 7ml peripheral blood
Description: puncture peripheral vein

Intervention type: PROCEDURE
Intervention: Drawing of 7ml peripheral blood
Description: puncture peripheral vein

Intervention type: PROCEDURE
Intervention: Drawing of 7ml peripheral blood
Description: puncture peripheral vein
Study: NCT03304262

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
Study: NCT02137304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
Description: Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
Study: NCT02232724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choline PET/CT and Dual time point FDG PET/CT
Description: Choline PET/CT and dual time point FDG PET/CT
Study: NCT00441480

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols esters
Description: 1.6g phytosterols and 1.3g omega-3 fatty acids per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 gr of corn oil
Study: NCT03736668

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
Study: NCT02644252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Carboplatin AUC=5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Vinorelbine 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Vinorelbine 30 mg/m2
Study: NCT02273414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS - rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00663338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
Study: NCT00418301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulation and PET Scan
Description: Imaging procedure to assess spinal Cord Stimulation.
Study: NCT02644252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 8: Capsule vinorelbine 60 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 8: Capsule vinorelbine 60 mg/m2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol 300 mg x 3 daily until progression

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol 300 mg x 3 daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1 capsule x 3 daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1 capsule x 3 daily until progression
Study: NCT05841927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplement
Description: Docosahexaenoic acid supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ASD placebo
Description: ASD placebo
Study: NCT05918731

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Management
Description: A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file.
Study: NCT02384135

Intervention type: OTHER
Group type: OTHER
Intervention: Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off
Study: NCT03321838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: accommodative/vergence therapy
Description: Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.